Current Edition

diabetes

Lawmakers blast pharma for ‘outrageous’ prices and ‘anticompetitive conduct’ in culmination of 3-year probe

For years, drugmakers have targeted “weaknesses” in the U.S. healthcare system to reap dividends on older meds, The House Oversight Committee said Friday. The “outrageous …

Continue Reading →
AbbVie

AbbVie’s Rinvoq notches Crohn’s disease win amid classwide JAK safety concerns

AbbVie’s blockbuster hopeful Rinvoq notched a win in a tricky-to-treat group of Crohn’s disease patients, potentially adding another arrow to the company’s post-Humira quiver. The …

Continue Reading →
AbbVie

Alvotech, battling AbbVie over its Humira biosim, raises $450M and tees up Nasdaq debut

Alvotech, the biosim specialist locked in a legal battle over AbbVie’s sales Goliath Humira, is revving up for its debut on the Nasdaq. The Icelandic …

Continue Reading →
AbbVie

AbbVie’s Imbruvica patent win sets up solid growth path after Humira’s decline: analyst

Don’t sleep on AbbVie’s recent federal court victory which upheld its patents on big-selling cancer drug Imbruvica, warns one influential biopharma analyst. In the case, …

Continue Reading →